We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids
Read MoreHide Full Article
Allergan plc announced that the FDA has approved its supplemental biologics license application (sBLA) to expand the label of its blockbuster product Botox for pediatric patients with upper limb spasticity. Botox is approved for the indication in adults.
With the approval, Botox becomes the first neurotoxin treatment approved for upper limb spasticity in children aged 2 to 17 years. The FDA approval was based on data from two phase III studies conducted in over 200 pediatric patients with the disease.
We remind investors that the FDA had granted priority review to the sBLA in March. Another sBLA looking for approval of Botox for pediatric lower limb spasticity indication is also under FDA’s review with a decision expected in the fourth quarter. Botox is also approved for this indication in adults.
So far this year, Allergan’s share price has declined 2.2% compared with the industry’s decrease of 12.8%.
Approved for therapeutic and aesthetic use, Botox is a key top-line driver for Allergan. Its cosmetic indications include three facial aesthetic treatments — forehead lines, crow’s feet wrinkles at the outer corner of eyes and glabellar lines.
Botox’s is approved for several therapeutic indications including overactive bladder, cervical dystonia and strabismus among others.
Notably, Botox is one of the key revenue catalysts for Allergan. The drug generated sales of $868.4 million (both cosmetic and therapeutic) in the first quarter of 2019, up 6.3% year over year.
However, there have been concerns regarding possible new competitors to Botox, mainly for its therapeutic uses, which can pull down the blockbuster drug’s sales in the future quarters.
The entry of calcitonin gene-related peptide (CGRP) antibodies in 2018 may have a negative impact on sales of Botox for the chronic migraine indication. Amgen (AMGN - Free Report) , Eli Lilly (LLY - Free Report) and Teva Pharma’s (TEVA - Free Report) CGRP migraine treatments, Aimovig, Emgality and Ajovy, respectively were all launched in 2018.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids
Allergan plc announced that the FDA has approved its supplemental biologics license application (sBLA) to expand the label of its blockbuster product Botox for pediatric patients with upper limb spasticity. Botox is approved for the indication in adults.
With the approval, Botox becomes the first neurotoxin treatment approved for upper limb spasticity in children aged 2 to 17 years. The FDA approval was based on data from two phase III studies conducted in over 200 pediatric patients with the disease.
We remind investors that the FDA had granted priority review to the sBLA in March. Another sBLA looking for approval of Botox for pediatric lower limb spasticity indication is also under FDA’s review with a decision expected in the fourth quarter. Botox is also approved for this indication in adults.
So far this year, Allergan’s share price has declined 2.2% compared with the industry’s decrease of 12.8%.
Approved for therapeutic and aesthetic use, Botox is a key top-line driver for Allergan. Its cosmetic indications include three facial aesthetic treatments — forehead lines, crow’s feet wrinkles at the outer corner of eyes and glabellar lines.
Botox’s is approved for several therapeutic indications including overactive bladder, cervical dystonia and strabismus among others.
Notably, Botox is one of the key revenue catalysts for Allergan. The drug generated sales of $868.4 million (both cosmetic and therapeutic) in the first quarter of 2019, up 6.3% year over year.
However, there have been concerns regarding possible new competitors to Botox, mainly for its therapeutic uses, which can pull down the blockbuster drug’s sales in the future quarters.
The entry of calcitonin gene-related peptide (CGRP) antibodies in 2018 may have a negative impact on sales of Botox for the chronic migraine indication. Amgen (AMGN - Free Report) , Eli Lilly (LLY - Free Report) and Teva Pharma’s (TEVA - Free Report) CGRP migraine treatments, Aimovig, Emgality and Ajovy, respectively were all launched in 2018.
Allergan currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>